Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
暂无分享,去创建一个
F. Blanco | F. Navarro | A. Fernández-Nebro | J. Álvaro-Gracia | M. Guzmán | Y. Armendáriz | A. García-López | S. Bustabad | J. Román-Ivorra